Recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors NCT05581004 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +57 more Locations Stanford University — San Francisco, California, United States University Of Colorado — Aurora, Colorado, United States Florida Cancer Specialists - Sarasota — Sarasota, Florida, United States Winship Cancer Institute — Atlanta, Georgia, United States View all 41 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma NCT07571551 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more Locations Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University — Nanjing, Jiangsu, China View Trial Details
Completed MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) NCT03108066 Conditions Abnormalities, Multiple, Adenocarcinoma, Angiomatosis, +35 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
